The first patient has been dosed with a treatment for agitation in patients with Alzheimer’s disease (AD) dementia. 

The Phase II/III SERENADA trial is evaluating the efficacy and safety of Deraphan, developed by biopharmaceutical company Exciva. 

Deraphan is a combination of two clinically validated products: dextromethorphan, an NMDA receptor channel blocker, and Deramciclane, a triple-acting agent that is a CYP2D6 inhibitor and a 5-HT2A/2C receptor inverse agonist. The combination is designed to deliver a broad and synergistic treatment targeting various neuropsychiatric symptoms associated with dementia, including agitation.  

Exciva’s approach in avoiding the dopaminergic system offers the potential to treat agitation without increasing the risk of cognitive decline, morbidity or mortality. If proven effective, Deraphan could become a novel and valuable option in improving the quality of life for patients living with AD. 

A Phase I trial of Deraphan previously demonstrated the treatment was safe and well-tolerated. 

“We are proud to announce the dosing of the first patient in SERENADA,” said François Conquet, CEO of Exciva. 

“We are thankful to Dr Michael Ropacki and the team at Esperanza Clinical for their role in supporting us in developing new treatment options for patients with AD dementia. With its promising therapeutic potential, it could pave the way to treating agitation in other neuropsychiatric disorders.” 

The start of the Phase II/III trial comes as Exciva announced Dolby Ventures has joined as a new investor, bringing the company’s Series B financing to €53 million. 

“Exciva’s approach to targeting neuropsychiatric symptoms, in particular agitation in Alzheimer’s patients, addresses a critical unmet need in Alzheimer’s care,” said Reetika Bhardwaj, principal at Dolby Ventures.  

“Our investment in Exciva underscores our commitment to advancing therapeutic treatments in neurodegenerative diseases, which have profound societal and economic implications, and providing support for AD patients and carers worldwide.”